SCHEMBL425576

SCHEMBL425576

O=C(N1CCOCC1)n1cnc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.56
BCHE P06276 1/20 0.56
AKR1C3 P42330 4/20 0.53
PHGDH O43175 3/20 0.51
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
MGLL Q99685 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427298 0.86 TSHR (0.51) AKR1C3PHGDHSMN1; SMN2NPC1RAB9A
SCHEMBL425673 0.84 POLB (0.51) LIPEBCHESMN1; SMN2NPC1RAB9A
SCHEMBL425575 0.84 BCHE (0.56) LIPEBCHEAKR1C3TP53SMN1; SMN2
SCHEMBL425711 0.82 AKR1C3 (0.49) AKR1C3NPC1MAPTGAAPIK3CA
SCHEMBL426880 0.80 SCN9A (0.42) LIPEBCHETP53SMN1; SMN2NPC1
SCHEMBL425860 0.80 ALDH1A1 (0.46) LIPEBCHEAKR1C3SMN1; SMN2NPC1
SCHEMBL462380 0.79 MAP4K4 (0.38) LIPEBCHEHPGDPOLB
SCHEMBL427075 0.79 BRD4 (0.38) LIPEBCHEHPGDPOLB
SCHEMBL427456 0.78 SCN5A (0.51) LIPEBCHEMAPK1MEN1KMT2A
SCHEMBL427651 0.78 SCN7A (0.48) LIPEBCHETP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 LIPE 61/4885BCHE 93/4885AKR1C3 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.